FCMV
CRVS icon

Foresite Capital Management VI’s Corvus Pharmaceuticals CRVS Stock Holding History

Foresite Capital Management VI’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.4M Hold
1,831,233
– – 4.26% 7
2026
Q1 		$26.8M Buy
1,831,233
+450,000
+33% +$7.18M 5.82% 4
2025
Q4 		$10.6M Sell
1,381,233
-350,000
-20% -$2.76M 3.21% 11
2025
Q3 		$12.8M Hold
1,731,233
– – 4.93% 7
2025
Q2 		$6.92M Buy
1,731,233
+150,000
+9% +$546K 3.89% 9
2025
Q1 		$5.03M Hold
1,581,233
– – 2.75% 10
2024
Q4 		$8.46M Buy
+1,581,233
New +$11.8M 3.77% 9

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Foresite Capital Management VI's CRVS Position: Q2 2026 in Review

Foresite Capital Management VI held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 1,831,233 shares worth $27.4M. The position accounts for 4.26% of the portfolio, ranked #7.

Foresite Capital Management VI first reported a position in CRVS in Q4 2024 and has held it in 7 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Foresite Capital Management VI held 1,831,233 shares of Corvus Pharmaceuticals worth $27.4M as of Q2 2026.
  • Foresite Capital Management VI left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
  • Corvus Pharmaceuticals made up 4.26% of Foresite Capital Management VI's portfolio in Q2 2026, its #7 holding.
  • Foresite Capital Management VI first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Foresite Capital Management VI's 13F filing for Q2 2026, filed 14 Aug 2026.